Skip to main content

Table 1 Clinical and laboratory data of patients who had HSCT in the BMT unit

From: Liver disease during and after hematopoietic stem cell transplantation in adults: a single-center Egyptian experience

Variable 
SexMale/female121/69
Type of transplantationAutologous88 (46%)
Allogeneic102 (54%)
Type of illnessMultiple myeloma47(24.7%)
AML44(23.1%)
Lymphoma41(21.5%)
ALL30(15.7%)
Severe aplastic anemia16 (8.4%)
Chronic myeloid leukemia7 (3.7%)
Myelodysplastic syndrome5 (2.6%)
Virology pre-transplantHBV31(16.3%)
HCV36 (19%)
CMV15 (8%)
Mobilization protocolVAD23(22.3%)
DHAP38(36.9%)
Velcade/dexamethasone31(30.1%)
Endoxan/G-CSF38(36.9%)
Conditioning regimen for autologous transplantMelphalan45(51.1%)
Carboplatin/VP16/CY19(21.5%)
Melphalan/VP1616(14.7%)
Conditioning regimen for allogeneic transplantBU +FLU51 (50%)
BU +CY16(15.6%)
TBI +CY13(12.7%)
CY+FLU+ATG10 (9.8%)